ALECSAT - CytoVac
Alternative Names: ALECSATLatest Information Update: 28 Jul 2024
At a glance
- Originator CytoVac
- Class Cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Glioblastoma; Sarcoma
- Phase I/II Triple negative breast cancer
- No development reported Pancreatic cancer; Prostate cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer in Denmark (IV, Injection)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Prostate-cancer in Denmark (IV, Injection)
- 23 Jul 2022 Phase I/II development in Triple-negative-breast cancer (Metastatic disease, Adjunctive treatment, Late-stage disease) is ongoing in Denmark (IV) (NCT04609215) (EudraCT2019-001420-34)